These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 26400668)
1. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668 [TBL] [Abstract][Full Text] [Related]
2. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008 [TBL] [Abstract][Full Text] [Related]
3. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932 [TBL] [Abstract][Full Text] [Related]
5. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Takeuchi S; Yano S Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378 [TBL] [Abstract][Full Text] [Related]
7. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity. Xu Y; Huang Z; Gong L; Fan Y Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841 [TBL] [Abstract][Full Text] [Related]
9. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428 [TBL] [Abstract][Full Text] [Related]
10. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581 [TBL] [Abstract][Full Text] [Related]
11. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Suda K; Mizuuchi H; Maehara Y; Mitsudomi T Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441 [TBL] [Abstract][Full Text] [Related]
12. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838 [TBL] [Abstract][Full Text] [Related]
13. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Gou LY; Li AN; Yang JJ; Zhang XC; Su J; Yan HH; Xie Z; Lou NN; Liu SY; Dong ZY; Gao HF; Zhou Q; Zhong WZ; Xu CR; Wu YL Oncotarget; 2016 Aug; 7(32):51311-51319. PubMed ID: 27259997 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320 [TBL] [Abstract][Full Text] [Related]
15. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664 [TBL] [Abstract][Full Text] [Related]
16. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related]
17. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188 [TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230 [TBL] [Abstract][Full Text] [Related]
19. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]